Guggenheim maintains Buy rating on Compass Therapeutics, $4 price target
Guggenheim maintained their Buy rating on Compass Therapeutics's stock with a price target of $4.00.The price target implies an upside of 222.6% from the Sep 22 close of $1.24.Key takeaways from the analyst noteStrong Pipeline Potential: Compass Therapeutics has a robust pipeline of innovative prod…